Date | Time | Source | Headline | Symbol | Company |
07/30/2024 | 6:26AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
07/30/2024 | 6:00AM | IH Market News | Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots | NASDAQ:AZN | AstraZeneca PLC |
07/29/2024 | 7:00AM | Business Wire | Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
07/29/2024 | 6:00AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 7:00AM | Business Wire | AstraZeneca’s H1 and Q2 2024 Financial Results | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 6:21AM | IH Market News | U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations | NASDAQ:AZN | AstraZeneca PLC |
07/25/2024 | 6:19AM | IH Market News | Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% | NASDAQ:AZN | AstraZeneca PLC |
07/23/2024 | 7:00AM | PR Newswire (Canada) | Voydeya est approuvé au Canada à titre de traitement d'appoint au ravulizumab ou à l'éculizumab chez les adultes atteints d'une maladie rare, appelée HPN, qui présentent une anémie hémolytique résiduelle attribuable à une hémolyse extravasculair | NASDAQ:AZN | AstraZeneca PLC |
07/23/2024 | 7:00AM | PR Newswire (Canada) | Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis | NASDAQ:AZN | AstraZeneca PLC |
06/25/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
06/17/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer | NASDAQ:AZN | AstraZeneca PLC |
06/16/2024 | 7:00AM | Business Wire | CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
06/12/2024 | 5:35PM | Business Wire | FARXIGA approved in the US for the treatment of pediatric type-2 diabetes | NASDAQ:AZN | AstraZeneca PLC |
06/12/2024 | 10:14AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/10/2024 | 7:00AM | Business Wire | TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer | NASDAQ:AZN | AstraZeneca PLC |
06/06/2024 | 7:00AM | PR Newswire (US) | I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 4:23PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 10:02AM | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 9:10AM | IH Market News | Economic Worries May Lead To Weakness On Wall Street | NASDAQ:AZN | AstraZeneca PLC |
06/04/2024 | 7:00AM | PR Newswire (US) | AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 10:29AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 10:23AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/03/2024 | 6:35AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 2:32PM | Business Wire | TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 8:05AM | Business Wire | IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo | NASDAQ:AZN | AstraZeneca PLC |
06/02/2024 | 8:00AM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 4:30PM | GlobeNewswire Inc. | Cellectis Reports Financial Results for First Quarter 2024 | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 9:06AM | Business Wire | ダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示す | NASDAQ:AZN | AstraZeneca PLC |
05/28/2024 | 6:15AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
05/27/2024 | 4:55PM | Business Wire | Datopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem Lungenkrebs | NASDAQ:AZN | AstraZeneca PLC |